Association of the DRD and OXT Genetic Polymorphisms With Schizophrenia in a Chinese Population.

IF 1.6 4区医学 Q3 CLINICAL NEUROLOGY

Journal of Nervous and Mental Disease Pub Date : 2025-03-01 Epub Date: 2025-02-24 DOI:10.1097/NMD.0000000000001824

Jingjing Li, Wen Bi, Mengqiu Xiong, Lubanga Nasifu, Lingyun Zhang, Chengbin Zhu, Bangshun He

{"title":"Association of the DRD and OXT Genetic Polymorphisms With Schizophrenia in a Chinese Population.","authors":"Jingjing Li, Wen Bi, Mengqiu Xiong, Lubanga Nasifu, Lingyun Zhang, Chengbin Zhu, Bangshun He","doi":"10.1097/NMD.0000000000001824","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>The polymorphism of dopamine receptor (DRD) and oxytocin (OXT) may be associated with schizophrenia. A case-control study of 248 schizophrenia patients and 236 controls was conducted using the Sequenom MassARRAY platform. The results showed that DRD2 rs1800497 was a heterozygote (AG vs. GG: adjusted odds ratio [OR] = 1.88; 95% confidence interval [CI]: 1.09-3.25) and DRD3 rs7631540 (TC vs. CC: adjusted OR = 0.60; 95% CI: 0.36-1.02) may be associated with an increased risk of developing schizophrenia. In addition, the DRD2 rs1800497 genotype GA showed a reduced risk of schizophrenia in the male subgroup and the late-onset subgroup (>27 years of age). For DRD3 polymorphisms, the rs7631540 TC genotype was associated with schizophrenia in the female subgroup. In OXT polymorphism analysis, rs2740210 codominant CA/AA was a risk factor for schizophrenia in the male and early-onset subgroup (≤27 years old). This study also concluded that OXT rs2740210 codominant CA/AA is associated with schizophrenia.</p>","PeriodicalId":16480,"journal":{"name":"Journal of Nervous and Mental Disease","volume":" ","pages":"71-77"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nervous and Mental Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/NMD.0000000000001824","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: The polymorphism of dopamine receptor (DRD) and oxytocin (OXT) may be associated with schizophrenia. A case-control study of 248 schizophrenia patients and 236 controls was conducted using the Sequenom MassARRAY platform. The results showed that DRD2 rs1800497 was a heterozygote (AG vs. GG: adjusted odds ratio [OR] = 1.88; 95% confidence interval [CI]: 1.09-3.25) and DRD3 rs7631540 (TC vs. CC: adjusted OR = 0.60; 95% CI: 0.36-1.02) may be associated with an increased risk of developing schizophrenia. In addition, the DRD2 rs1800497 genotype GA showed a reduced risk of schizophrenia in the male subgroup and the late-onset subgroup (>27 years of age). For DRD3 polymorphisms, the rs7631540 TC genotype was associated with schizophrenia in the female subgroup. In OXT polymorphism analysis, rs2740210 codominant CA/AA was a risk factor for schizophrenia in the male and early-onset subgroup (≤27 years old). This study also concluded that OXT rs2740210 codominant CA/AA is associated with schizophrenia.

查看原文本刊更多论文

中国人群中DRD和OXT基因多态性与精神分裂症的关系

摘要：多巴胺受体（DRD）和催产素（OXT）多态性可能与精神分裂症有关。采用Sequenom MassARRAY平台对248名精神分裂症患者和236名对照者进行病例对照研究。结果显示，DRD2 rs1800497为杂合子(AG vs. GG：校正优势比[OR] = 1.88；95%置信区间[CI]: 1.09-3.25)和DRD3 rs7631540 (TC vs. CC：调整OR = 0.60；95% CI: 0.36-1.02)可能与患精神分裂症的风险增加有关。此外，DRD2 rs1800497基因型GA在男性亚组和晚发亚组（bb0 ~ 27岁）中显示精神分裂症的风险降低。对于DRD3多态性，rs7631540 TC基因型与女性亚组的精神分裂症相关。在OXT多态性分析中，rs2740210共显性CA/AA是男性和早发亚组（≤27岁）精神分裂症的危险因素。本研究还得出OXT rs2740210共显性CA/AA与精神分裂症相关的结论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nervous and Mental Disease 医学-精神病学

CiteScore

2.90

自引率

5.30%

发文量

233

审稿时长

3-8 weeks

期刊介绍： The Journal of Nervous and Mental Disease publishes peer-reviewed articles containing new data or ways of reorganizing established knowledge relevant to understanding and modifying human behavior, especially that defined as impaired or diseased, and the context, applications and effects of that knowledge. Our policy is summarized by the slogan, "Behavioral science for clinical practice." We consider articles that include at least one behavioral variable, clear definition of study populations, and replicable research designs. Authors should use the active voice and first person whenever possible.